>
Switch to:

Travere Therapeutics Enterprise Value

: $1,376.5 Mil (As of Today)
View and export this data going back to 2003. Start your Free Trial

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Travere Therapeutics's Enterprise Value is $1,376.5 Mil. Travere Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2020 was $-169.7 Mil. Therefore, Travere Therapeutics's EV-to-EBIT ratio for today is -8.11.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Travere Therapeutics's Enterprise Value is $1,376.5 Mil. Travere Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2020 was $-145.2 Mil. Therefore, Travere Therapeutics's EV-to-EBITDA ratio for today is -9.48.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Travere Therapeutics's Enterprise Value is $1,376.5 Mil. Travere Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2020 was $198.3 Mil. Therefore, Travere Therapeutics's EV-to-Revenue ratio for today is 6.94.


Travere Therapeutics Enterprise Value Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are indicated in the company's associated stock exchange currency.

* Premium members only.

Travere Therapeutics Annual Data
Feb11 Feb12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Enterprise Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 506.12 574.05 682.65 418.20 1,277.78

Travere Therapeutics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Enterprise Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 418.20 480.56 791.56 698.27 1,277.78

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Travere Therapeutics Enterprise Value Distribution

* The bar in red indicates where Travere Therapeutics's Enterprise Value falls into.



Travere Therapeutics Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Travere Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2020 is calculated as

Travere Therapeutics's Enterprise Value for the quarter that ended in Dec. 2020 is calculated as

* All numbers are in millions except for per share data and ratio. All numbers are indicated in the company's associated stock exchange currency.


Travere Therapeutics  (NAS:TVTX) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Travere Therapeutics's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1376.518/-169.739
=-8.11

Travere Therapeutics's current Enterprise Value is $1,376.5 Mil.
Travere Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2020 was -13.281 (Mar. 2020 ) + -21.369 (Jun. 2020 ) + -17.759 (Sep. 2020 ) + -117.33 (Dec. 2020 ) = $-169.7 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Travere Therapeutics's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=1376.518/-145.16
=-9.48

Travere Therapeutics's current Enterprise Value is $1,376.5 Mil.
Travere Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2020 was -7.625 (Mar. 2020 ) + -15.518 (Jun. 2020 ) + -11.32 (Sep. 2020 ) + -110.697 (Dec. 2020 ) = $-145.2 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Travere Therapeutics's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1376.518/198.321
=6.94

Travere Therapeutics's current Enterprise Value is $1,376.5 Mil.
Travere Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2020 was 47.769 (Mar. 2020 ) + 48.43 (Jun. 2020 ) + 51.139 (Sep. 2020 ) + 50.983 (Dec. 2020 ) = $198.3 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are indicated in the company's associated stock exchange currency.


Travere Therapeutics Enterprise Value Related Terms


Travere Therapeutics Enterprise Value Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)